Volume 6 Supplement 6
RNA-Seq analysis of two brain regions vulnerable to Alzheimer's disease
© Wang; licensee BioMed Central Ltd. 2012
Published: 1 October 2012
Alzheimer's disease (AD), one of the most devastating neurodegenerative diseases, does not affect different brain regions equally. The temporal and frontal lobes are among the brain regions most affected in AD. As the transcriptomic profile of neurons in a certain brain region largely affects their response to pathological conditions like AD, comparative transcriptomic analysis of these susceptible regions can be used to understand why they are particularly vulnerable to the disease. With rapid advances in next-generation sequencing technologies, RNA-Seq, or whole-transcriptome shotgun sequencing, has begun to become a mainstream approach to study brain regions that are affected by neurodegenerative diseases, including AD.
Materials and methods
In this study, RNA-Seq data that have recently become available  from both normally aged and AD brain temporal and frontal lobes (Sequence Read Archive [http://www.ncbi.nlm.nih.gov/sra]; accessions SRX035166, SRX035171, SRX035167 and SRX034874) were analyzed, in order to provide molecular insights into their common vulnerability while accounting for their regional specificities.
Here we present transcriptomic similarities and differences between the temporal and frontal lobes as detected by RNA-Seq. Interpretation of their similarities helps understand their shared vulnerability to AD. Detection of their differences in both normal aging and AD helps elucidate the progression of this disease in the two different regions.
The study of AD from the perspective of selective regional vulnerability is the first step towards minimizing its devastating effect on patients through protecting vulnerable brain neurons.
The author is supported by NIH grants including NIGMS 1P20GM103638-01, NIA P30 AG035982, NIA P01 AG12993 and NICHD P30 HD02528, and the Miller-Hedwig and Wilbur Fund.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.